FDAnews Drug Daily Bulletin

Aptalis Launches Viokace Tablets in U.S.

Aug. 16, 2012
Aptalis Pharma, a specialty pharmaceutical company, has announced the commercial availability of Viokace (pancrelipase) tablets in the U.S. Viokace, in combination with a proton pump inhibitor, is indicated in adults for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy.
Pharmaceutical Business Review